The role of vitamin D in sarcoidosis

Fabiola Gianella 2  Connie C.W. Hsia 2,3  Khashayar Sakhaee 1,3*

1 Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
2 Pulmonary and Critical Care Medicine Division, University of Texas Southwestern Medical Center, Dallas, Texas, USA
3 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Abstract

After the initial description of extrarenal synthesis of 1,25-dihydroxyvitamin D (1,25-(OH)2D) three decades ago, extensive progress has been made in unraveling the immunomodulatory roles of vitamin D in the pathogenesis of granulomatous disorders, including sarcoidosis. It has been shown that 1,25-(OH)2D has dual effects on the immune system, including upregulating innate immunity as well as downregulating the autoimmune response. The latter mechanism plays an important role in the pathogenesis and treatment of sarcoidosis. Vitamin D supplementation in patients with sarcoidosis has been hampered owing to concerns about the development of hypercalcemia and hypercalciuria given that extrarenal 1-α hydroxylase is substrate dependent. Recently, a few studies have cast doubt over the mechanisms underlying the development of hypercalcemia in this population. These studies demonstrated an inverse relationship between the level of vitamin D and severity of sarcoidosis. Consequently, clinical interest has been piqued in the use of vitamin D to attenuate the autoimmune response in this disorder. However, the development of hypercalcemia and the attendant detrimental effects are real possibilities. Although the average serum calcium concentration did not change following vitamin D supplementation, in two recent studies, hypercalciuria occurred in one out of 13 and two out of 16 patients. This review is a concise summary of the literature, outlining past work and newer developments in the use of vitamin D in sarcoidosis. We feel that larger-scale placebo-controlled randomized studies are needed in this population. Since the current first-line treatment of sarcoidosis is glucocorticoids, which confer many systemic adverse effects, and steroid-sparing immunosuppressant treatment options carry additional risks of adverse effects, adjunct management with vitamin D in combination with potent anti-osteoporotic medications could minimize the risk of glucocorticoid-induced osteoporosis and modulate the immune system to attenuate disease activity in sarcoidosis.

Keywords

Sarcoidosis, hypercalcemia, kidney stones, vitamin D, autoimmune

Peer Review

The peer reviewers who approve this article are:

1. Martin Hewison, Institute of Metabolism and Systems Research, The University of Birmingham, Birmingham, UK
   Competing interests: No competing interests were disclosed.

2. Mark Bolland, Department of Medicine, University of Auckland, Auckland, New Zealand
   Competing interests: No competing interests were disclosed.
Corresponding author: Khashayar Sakhaee (Khashayar.sakhaee@utsouthwestern.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: The authors’ work was supported by the Julius and Louise Truelson Fellowship fund in Mineral Metabolism, Frederic C. Bartter Fund for Young Investigators, Charles Y.C. Pak and Donald W. Seldin Center for Metabolic Research, and Laura Kim Pak Professorship in Mineral Metabolism Research.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Sakhaee K et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Gianella F, Hsia CCW and Sakhaee K. The role of vitamin D in sarcoidosis. Faculty Reviews 2020 9(14)
https://doi.org/10.12703/b/9-14

Published: 06 Nov 2020, Faculty Reviews 9(14) https://doi.org/10.12703/b/9-14
Introduction

Under normal circumstances, renal 1α-hydroxylase converts 25-hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25-(OH)2D). Evidence for increased circulating 1,25-(OH)2D and dysregulation of calcium metabolism in sarcoidosis was initially described in 1979. The underlying mechanisms for hypercalcemia were attributed to increased production and/or decreased catabolism of 1,25-(OH)2D. Several studies have indicated enhanced intestinal calcium absorption as the main mechanism for the development of hypercalcemia, hypercalciuria, nephrocalcinosis, and abnormal kidney function. A case report of hypercalcemia in an anephric patient with sarcoidosis was the first evidence for extrarenal production of 1,25-(OH)2D. Subsequent studies using cultured pulmonary alveolar macrophages and sarcoid lymph node homogenates explored the relationship between 25(OH)D and 1-α hydroxylase gene expression. Positive findings in the alveolar macrophages support the extrarenal conversion of 25(OH)D to 1,25-(OH)2D in sarcoidosis patients. These studies were pivotal in unraveling the immunomodulatory role of 1,25-(OH)2D in granulomatous diseases such as sarcoidosis and tuberculosis.

Here, we review evidence in two distinct ethnic populations with sarcoidosis; both sarcoidosis and vitamin D deficiency are more common in African Americans (AA) than in Caucasians. Moreover, clinical, biochemical, and mineral metabolic perturbations of sarcoidosis in these two distinct ethnicities were similar. Repletion of vitamin D in a small subset of vitamin D-deficient patients with sarcoidosis was found to be safe, effective, and associated with a fall in surrogate markers of sarcoidosis activity and, interestingly, with a fall in serum 1,25-(OH)2D. The underlying mechanism(s) of the observed response to vitamin D repletion in this population and the role of 24-hydroxylase in mediating this response deserve further investigation.

Epidemiology of sarcoidosis

Sarcoidosis is a multi-system inflammatory disorder associated with widespread granuloma deposition leading to multi-organ impairment. The complex causative factors dictate its heterogeneous presentation. Geography, race, age, and gender modulate the presentation of sarcoidosis, and it is most prevalent in the Northern hemisphere and among AA individuals. Studies in Northern Europe and Japan have described a bimodal age-specific incidence rate among women, with a first peak between 30 and 35 years of age and a second peak over 50 years of age.

The incidence and prevalence of sarcoidosis was greater in females than in males in most but not all studies. One study in Switzerland found no gender differences in incidence and prevalence of sarcoidosis, while another study in Sweden found a higher incidence in men than in women. The incidence of sarcoidosis in men peaks before 40 years of age; the incidence in women remains flat between the ages of 30 and 60 years. The higher prevalence and severity of sarcoidosis among the AA population was purported to be associated with lower vitamin D stores in this group. This notion was based on the immunomodulatory effects of vitamin D on the adaptive immune system, which is responsible for the suppression of granulomatous inflammation. However, our study in Dallas comprising a total of 86 patients with sarcoidosis from two separate ethnic groups from the United States (93% AA) and Italy (95% Caucasian) showed no difference in the clinical, biochemical, vitamin D, and mineral profiles in these two distinct populations.

Renal synthesis and classical action of 1,25-(OH)2D

Vitamin D3 (cholecalciferol) is synthesized from exposure to ultraviolet radiation transforming 7-dehydrocholesterol in the skin to vitamin D3. In addition, vitamin D3, found in the circulation following the consumption of fortified dairy products, orange juice, and fish. Vitamin D2 (ergocalciferol) is also synthesized from ergosterol by exposure to ultraviolet radiation. Vitamin D3 is found naturally in mushrooms, vitamin D supplements, and with food fortification. Nonetheless, both vitamin D2 and vitamin D3 undergo the same metabolic pathway.

Circulating vitamin D is initially hydroxylated by three different 25-hydroxylase enzymes (CYP27A1, CYP2R1, and CYP3A4) in the liver, producing 25(OH)D. 25(OH)D undergoes another hydroxylation by 25(OH)D-1-α hydroxylase (CYP27B1) in the kidney, resulting in the production of 1,25-(OH)2D, the most active vitamin D metabolite. 25(OH)D and 1,25(OH)2D also undergo 24-hydroxylation by 24-hydroxylase (CYP24A1) to produce inactive metabolites. 24,25-(OH)2D and 1,24,25-trihyrdroxyvitamin D, respectively. The activity of renal CYP27B1 is tightly regulated. Parathyroid hormone (PTH) and hypophosphatemia stimulate 25(OH)D-1-α hydroxylase (CYP27B1) activity. Fibroblast growth factor 23 (FGF23) decreases CYP27B1 activity and stimulates CYP24A1 action.

Similar to other steroidal hormones, 1,25-(OH)2D acts upon a specific intracellular vitamin D receptor (VDR) to fulfill major classical functions on the target organs, including the enhancement of intestinal calcium, phosphate absorption, regulation of osteoclastic bone resorption, and osteoblastic bone formation (Figure 1).

Extra renal synthesis and non-classical action of 1,25-(OH)2D

It has been shown that monocytes, dendritic cells (DCs), macrophages, B-cells, and T-cells possess 25(OH)D-1-α hydroxylase activity locally to transform 25(OH)D into 1,25-(OH)2D. Similar to its classical action, the immunomodulatory effect of vitamin D (non-classical action) is exerted via the VDR within the immunomodulatory cells. This immunomodulatory function plays a key role in the pathogenesis of granulomatous disorders, specifically in sarcoidosis and tuberculosis.

Unlike renal (CYP27B1) activity, extrarenal 25(OH)D-1-α hydroxylase CYP27B1 activity is highly substrate dependent, and its production is significantly affected by the prevailing serum
concentration of 25(OH)D\textsuperscript{60}. Therefore, the local production of 1,25-(OH)\_2D is deficient when serum concentration of 25(OH)D is low (below 25 ng/mL)\textsuperscript{60}.

**Vitamin D and innate immunity**

The effect of vitamin D on the innate immune response is exerted via antigen presentation by macrophages or DCs, the principal cells which mediate the anti-bacterial effect against *Mycobacterium tuberculosis* (M.tb)\textsuperscript{61}. The ability of monocytes and macrophages to attack M.tb phagocytosis but also on sensing pathogen-associated molecular patterns (PAMPS) via specific pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs)\textsuperscript{62}. TLRs are a family of noncatalytic transmembrane PRRs that interacts with specific PAMPS\textsuperscript{63,64}. It was shown that intracrine induction of CYP27B1 and VDR by monocytes follows PAMP sensing by TLRs\textsuperscript{66}. This interaction results in the production of cathelicidins, a class of host defense peptides that facilitate microbial killing\textsuperscript{61,66,67} (Figure 2). Granuloma formation may result from defects in innate immunity that impair the elimination of inciting antigens\textsuperscript{68}. Since mycobacterial antigens have been implicated in the pathogenesis of sarcoidosis, several studies have suggested that the cathelicidins act as a bridge between sarcoidosis and tuberculosis\textsuperscript{69}, and deficiency of cathelicidins in macrophages has been implicated in severe tuberculosis and sarcoidosis\textsuperscript{70}. In this study, alveolar macrophage–cathelicidin mRNA expression, VDR, and the VDR coactivator steroid receptor coactivator-3 (SRC3) were measured by quantitative PCR in alveolar macrophages from bronchoalveolar lavage in patients with biopsy-proven sarcoidosis and healthy controls. Results showed
reduced alveolar macrophage expression of cathelicidin and SRC3 in severe but not in non-severe sarcoidosis patients compared to controls\(^7\). Further in vitro studies showed that tumor necrosis factor (TNF-\(\alpha\)) (a vitamin D3 antagonist) mediates the suppression of SRC3, leading to alveolar macrophage cathelicidin deficiency in severe sarcoidosis.

In a recent prospective case-control study, serum 25(OH)D and cathelicidin levels were measured in 30 patients with active pulmonary tuberculosis, 30 patients with sarcoidosis, and 20 healthy control subjects. Results showed severe vitamin D deficiency in 47% of patients with sarcoidosis compared with 3% in those with tuberculosis\(^6\). Moreover, cathelicidin levels were significantly higher in control subjects than in sarcoidosis or tuberculosis patients; there was no significant difference in cathelicidin levels between tuberculosis and sarcoidosis patients\(^6\). An optimum cathelicidin cut-off value of 107.14 pg/mL, with a sensitivity of 81.5% and specificity of 71.2%, was found to differentiate sarcoidosis patients from healthy control subjects.

**Vitamin D and adaptive immunity**

Vitamin D action via adaptive immunity may attenuate overzealous inflammatory responses, thus protecting against tissue damage. This action has been demonstrated through downregulation of TLR2 and TLR4 expression in monocytes\(^7\) and attenuation of T-helper type 1 (Th1) lymphocytes known to increase autoimmune response\(^6\). The beneficial effects of 1,25-(OH)\(_2\)D are exerted by balancing the pro-inflammatory cytokines by Th1 cells that produce pro-inflammatory cytokines (including IL-2, IFN-\(\gamma\), and TNF-\(\alpha\)) and Th2 cells that produce anti-inflammatory cytokines (including IL-3, IL-4, IL-5, and IL-10)\(^6,72-75\) (Figure 2).

In addition, two other T-cell groups, Th17 and T-regulatory cells, play a role in the suppression of autoimmunity\(^76-78\) in response to 1,25-(OH)\(_2\)D. Given the anti-microbial and anti-inflammatory properties of 1,25-(OH)\(_2\)D, it has been suggested that extra renal hydroxylation of 25-OH-D and 1,25-(OH)\(_2\)D represents an adaptive response aimed at minimizing inflammation, protecting against tissue destruction, and eliminating the inciting antigens that cause sarcoidosis\(^79\).

**Vitamin D in sarcoidosis: a current paradigm**

Sarcoidosis and vitamin D deficiency are more common and more severe in AA than in Caucasians in the US\(^26-32\). Previous studies have shown an inverse association between serum 25-(OH)D and severity of sarcoidosis activity\(^80-82\). Excess 1,25-(OH)\(_2\)D has been perceived as detrimental, mainly because of concerns for the development of hypercalcemia. However, it is possible that excess production of 1,25-(OH)\(_2\)D in sarcoidosis is an adaptive immune mechanism to mitigate granulomatous inflammation by promoting the removal of inciting antigen to protect tissue integrity. Concern over complications of vitamin D supplementation at the dosage normally insufficient to induce alteration in serum and urinary calcium levels in healthy subjects has hampered research into the role of vitamin D supplementation in sarcoidosis\(^81,83,84\). However, the incidence of hypercalcemia in sarcoidosis spans a wide range in different populations. In recent studies, the incidence of hypercalcemia ranges from 5.2–7.7% in sarcoidosis patients treated with calcium and vitamin D supplementation\(^12,80,85\).

Limited studies have addressed mineral status before and after treatment with calcium and vitamin D (Table 1). In 1979,
**Table 1. Studies of vitamin D and Ca supplementation in sarcoidosis.**

| First author            | Mark J. Bolland⁸⁵  | Giovanna Capolongo¹² | Lieke S. Kamphuis¹⁰ | Norman H. Bell¹¹ |
|-------------------------|---------------------|----------------------|---------------------|-----------------|
| Year                    | 2013                | 2016                 | 2014                | 1979            |
| Design                  | Randomized, placebo controlled | Non-randomized | Retrospective       | Non-randomized  |
| Number of patients      | 27                  | 86                   | 301                 | 7               |
| Type of patients        | Normocalcemic sarcoidosis with 25-(OH)D <50 nmol | Sarcoidosis patients with serum 25-(OH)D <75 nmol/L | Sarcoidosis patients | 4 normocalcemic patients and 3 patients with history of hypercalcemia |
| Age (years)             | 57                  | 51±6.7               | Unknown             | 22–64           |
| Female number (%)       | 19 (70%)            | 15 (93.7%)           | 174 (58%)           | 7 (50%)         |
| Race/ethnicity          | European (77%)      | Indian (8%)          | African American (88%) | Caucasian (12%) |
|                         | Indian (8%)         | Other (8%)           | Unknown             |                 |
| Number of patients treated with vitamin D | 13                  | 16                   | 104                 | 7               |

**Intervention**

| Type of vitamin D       | Cholecalciferol (vitamin D3) | Ergocalciferol (vitamin D2) | Vitamin D2 in propylene glycol was given daily as a single dose |
|-------------------------|------------------------------|----------------------------|------------------------------------------------------------------|
| Dose/frequency/duration | 50,000 IU weekly for 4 weeks then monthly for 11 months | 50,000 IU once a week for 12 weeks | 10,000 IU daily for 12 days |
| Diet                    | Usual diet                   | Usual Diet                 | Constant metabolic diet                                          |
| Glucocorticoid use      | 54% past oral use            | 48% US patients            | 40% of hypercalcemic patients                                    |
|                         | 8% current oral use          | 47% Italian patients       | Unknown                                                          |
|                         | 46% current inhaled use      |                             |                                                                  |

**Baseline laboratory parameters**

|                                     | Vitamin D (n = 13) | Placebo (n = 14) | Pre-vitamin D (n = 16) | Ca and vitamin D supplementation (n = 104) | Normal subjects (n = 7) | Patients with normal Ca metabolism (n = 4) |
|-------------------------------------|--------------------|------------------|------------------------|--------------------------------------------|------------------------|--------------------------------------------|
| 25-(OH)D (nmol/L)                   | 40±17              | 45±17            | 42±13                  | 46                                         | 67.4±14.9              | 37.4±12.4                                  |
| 1,25-(OH)2D (pmol/L)                | 109±34             | 116±25           | 94±30                  | 114                                        | 72±7.2                 | 70±7.2                                     |
| Serum phosphorus (mmol/L)           | 1.23±0.15          | 1.06±0.17        | 1.1                    | 1.1                                        |                        |                                            |
| Serum Ca (mmol/L)                   | 2.24±0.06          | 2.26±0.12        | 2.38±0.05              | 2.39                                       | 2.37±0.05              | 2.32±0.05                                  |
| Parathyroid hormone (pmol/L)        | 4.0±1.6            | 4.9±2.0          | 5.8±3.1                |                                            |                        |                                            |
| Urinary Ca (mmol/day)               | 4.6±3.4            | 6.6±5.2          | 3.4±2.3                |                                            | 5.17±0.55              | 3.42±0.45                                  |
### Outcome laboratory

|                            | Post-vitamin D repletion (n = 13) | Placebo (n = 14) | Post-vitamin D repletion (n = 16) | Ca and vitamin D supplementation (n = 104) | Normal subjects (n = 7) | Sarcoidosis patients with normal Ca metabolism (n = 4) |
|---------------------------|-----------------------------------|------------------|-----------------------------------|-------------------------------------------|------------------------|------------------------------------------------------|
| % hypercalcemia, n (%)    | 1 (7.6%)                          | 0                | 1 (6.2%)                          | 5% (4% excluding 1 patient with primary hyperparathyroidism at baseline) | 0                      | 0                                                   |
| % hypercalciuria, n (%)   | 1 (7.6%)                          | 0                | 2/16 (12.5%)                      | 0                                         | 0                      | 0                                                   |
| 25-(OH)D (nmol/L)         | 80 (68–93)                        | 48 (34–62)       | 81±25                             | 74                                        | 72.4±14.9               | 69.8±9.98                                           |
| 1,25-(OH)2D (pmol/L)      | 141 (114–174)                     | 127 (107–140)    | 49±21                             | 74                                        | 74.4±4.8               | 79.2±4.8                                            |
| Serum Ca (mmol/L)         | 2.24 (2.19–2.30)                  | 2.24 (2.18–2.29) | 2.40±0.15                         | 4.8±0.05                                  | 4.8±0.2                | 4.15±0.62                                           |
| Urinary Ca (mmol/day)     | 7.3 (3.4–11.1)                    | 5.3 (2.6–7.9)    | 4.2±3.3                           | 4.9±0.45                                  | 4.15±0.62                                           |

Results are expressed as mean ± SD. *Data are extracted from figures in Boland et al. and expressed as mean (95% CI). 25-(OH)D, 25-hydroxyvitamin-D; 1,25-(OH)2D, 1,25-dihydroxyvitamin D; Ca, calcium
Bell et al. implicated 1,25-(OH)₂D in abnormal calcium metabolism in three patients with sarcoidosis; treatment with prednisone corrected hypercalcaemia and normalized serum 1,25-(OH)₂D. To test whether the development of hypercalcaemia is due to the increased sensitivity to vitamin D, seven normal subjects and seven sarcoidosis patients were challenged with oral vitamin D (10,000 IU daily) for 12 days. In this short-term study, vitamin D administration did not change serum calcium, 1,25-(OH)₂D, or urinary calcium in normal subjects, while serum calcium, 1,25-(OH)₂D, and urine calcium increased in sarcoidosis patients. The investigators concluded that abnormal calcium metabolism reflects impaired regulation of the synthesis or catabolism of 1,25-(OH)₂D.

Bolland et al. in a randomized, placebo-controlled trial in New Zealand involving 27 normocalcemic patients with sarcoidosis and vitamin D insufficiency using 50,000 IU weekly cholecalciferol for 4 weeks followed by 50,000 IU monthly or placebo for 11 months, showed that vitamin D supplements did not change the mean serum calcium or urine calcium; one patient (7.7%) developed significant hypercalcaemia at a cumulative dose of 250,000 IU of cholecalciferol over 6 weeks.

Kamphius et al. in a retrospective study of 301 sarcoidosis patients over 23 years, showed that supplementation of calcium (500 mg) and vitamin D (400 IU) daily was associated with a significant negative correlation between serum 25-(OH)D levels and disease activity assessed by somatostatin receptor scintigraphy; hypercalcemia developed in five out of 104 (4.8%) patients.

Capolongo et al. studied two sarcoidosis populations of distinct ethnic and lifestyle backgrounds from the US and Italy and showed largely similar baseline clinical, biochemical, and mineral metabolism parameters. The prevalence of vitamin D insufficiency in patients was not different from that in the US and Italy population. In 16 AA patients with sarcoidosis and vitamin D deficiency, oral ergocalciferol (50,000 IU) weekly for 12 weeks did not alter mean serum calcium level; one patient developed hypercalcaemia (6.25%) (Figure 3), i.e. similar to the incidence in Bolland’s study (7.7%) in both prospective studies, the lack of significant changes in bone mineral density or improvement in lung function may be due to the small sample size.

An unanticipated finding in the study by Capolongo et al. is a decline in serum 1,25-(OH)₂D following vitamin D repletion (Figure 3). The mechanisms for the decline remain unclear; however, it is possible that, in the presence of vitamin D deficiency, extrarenal production of 1,25-(OH)₂D in sarcoidosis by immune cells is accentuated as an adaptive response to mitigate antigen-stimulated granuloma formation. While there are no human studies addressing the regulation of serum 1,25-(OH)₂D in sarcoidosis, a rodent study has shown that locally generated 1,25-(OH)₂D upregulates 24-hydroxylase, which in turn stimulates the conversion of 25-(OH)D and/or 1,25-(OH)₂D to the inactive 1,24,25(OH)₃D. However, it has been shown that

intrinsic stimulation of 24-hydroxylase protein expresses a truncated splice variant which may be functionally inactive. This variant protein maintains its binding and may inhibit the effect of 25-(OH)D, limiting substrate provision for excess 1,25-(OH)₂D production spilling over into extracellular space, causing hypercalcaemia, but may also mitigate an overzealous autoimmune response. If this hypothesis is validated in a controlled clinical trial, then vitamin D supplementation can be utilized in the treatment of sarcoidosis not only to downregulate the autoimmune response but also to spare steroid-related adverse effects.

Hypercalciuria and kidney stones in sarcoidosis

Hypercalciuria occurs in 50% of cases of sarcoidosis and increases the risk for calcium oxalate stone formation. Approximately 10–13.8% of patients with chronic sarcoidosis suffer from at least one symptomatic stone. In only 1% of patients with sarcoidosis, kidney stones are an initial manifestation of the disease. However, in 2.7% of patients, asymptomatic stones are present when sarcoidosis is diagnosed otherwise. In the study by Capolongo et al., the prevalence of kidney stones was 11% and 17%, respectively. In this study, kidney stones were associated with a high urinary calcium excretion, but no association was found between serum vitamin D and urinary calcium levels, suggesting that hypercalciuria is independent of serum 25-(OH)D and 1,25-(OH)₂D levels in this population and may be related to impairment in renal tubular calcium reabsorption as a result of interstitial renal tubule involvement by sarcoidosis.

The development of hypercalciuria in sarcoidosis has been attributed to increased intestinal calcium absorption and bone resorption. Excess 1,25-(OH)₂D increases gut calcium absorption, which increases renal filter load, while decreased serum PTH reduces renal tubular calcium reabsorption. The mechanisms of kidney stone formation in sarcoidosis are similar to those in idiopathic absorptive hypercalciuria because of the increased serum 1,25-(OH)₂D levels in the latter patients. Glucocorticoid treatment produces a significant fall in serum 1,25-(OH)₂D associated with decreased intestinal calcium absorption in sarcoidosis but not in absorptive hypercalciuria. Moreover, hypercalciuria in patients with sarcoidosis and high circulating 1,25-(OH)₂D levels may be due to increased osteoclastic bone resorption. A similar situation has been reported in normal subjects challenged with a large dose of 1,25-(OH)₂D, suggesting that hypercalciuria originates in part from excessive calcium mobilization from bone. Glucocorticoids are the first-line treatment to reduce endogenous 1,25-(OH)₂D and serum calcium levels, often within days. Typically, urinary calcium falls significantly a few days after normalization of serum calcium and 1,25-(OH)₂D levels in 7–10 days. A lack of response after 2 weeks of treatment should raise the possibility of primary hyperparathyroidism, malignancy, lymphoma, and multiple myeloma. It is customary to reduce
Figure 3. Serum and urine biochemical profiles in patients with sarcoidosis before and after vitamin D supplementation. Changes in (a) serum calcium, (b) urine calcium, (c) serum 25-hydroxyvitamin-D (25-(OH)D), and (d) serum 1,25-dihydroxyvitamin-D (1,25-(OH)₂D) and (e) relationship between changes in serum 1,25-(OH)₂D and 25-(OH)D before and after vitamin D repletion in 16 patients with active sarcoidosis and vitamin D deficiency. This figure was reproduced from Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis, Capolongo et al., 64, 1025–34, 2020 with permission from BMJ Publishing Group Ltd.

Figure 4. Urinary calcium excretion in non-stone formers and stone-forming subjects with sarcoidosis. Lack of significant relationship of 24 hour urinary calcium with serum 25-hydroxyvitamin-D (25(OH)D) (left panel) and 1,25-dihydroxyvitamin-D (1,25-(OH)₂D) (right panel) in patients with sarcoidosis. This figure was reproduced from Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis, Capolongo et al., 64, 1025–34, 2020 with permission from BMJ Publishing Group Ltd.

glucocorticoid dose within 4–6 weeks of treatment. In case of glucocorticoid failure, hydroxychloroquine or anti-fungal agents such as ketoconazole that inhibit 1-α hydroxylase activity in granuloma may be used as steroid-sparing agents. Immunosuppressive agents such as methotrexate and azathioprine may also be considered. In patients with recurrent kidney stones and persistent hypercalciuria, surgical intervention with shockwave lithotripsy is indicated.
Treatment of abnormal vitamin D metabolism in sarcoidosis

Given that treatment with calcium and vitamin D supplements is required along with the first line of treatment in the management of steroid-induced osteoporosis, this approach was accepted into the 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. However, the dosage of calcium and vitamin D must be carefully adjusted to avoid the development of hypercalcemia and hypercalciuria. If serum calcium or 24 hour urinary calcium rises above the normal upper limit (2.62 mmol/L) or urinary calcium above 400 mg/day (10 mmol/day) in males and >300 mg/day (7.5 mmol/day) in females, calcium supplements and dietary calcium should be adjusted and serum and urinary calcium levels monitored in 2 weeks. Withdrawal of supplements has been shown to reverse hypercalcemia in sarcoidosis.

If serum calcium is persistently elevated, then vitamin D dosage must be further adjusted with follow-up blood and urine chemistry. Bolland et al. proposed that given the nature of hypercalcemia development in this population remains unknown, a smaller dose of vitamin D may avoid complications of hypercalcemia; this issue would need to be examined in future prospective controlled trials. Dose adjustment of vitamin D supplement may reduce its benefits on skeletal health; furthermore, the exact dosage of vitamin D influencing its immunomodulatory role at tissue level has not been tested.

Bolland et al., based on modelling, proposed that it is not ethically feasible to conduct a clinical trial aimed at improving skeletal health because the risks of developing hypercalcemia exceed the benefits to bone health. This modelling was based on 13 patients who received vitamin D, in which only one patient developed hypercalcemia. Gallagher et al., in a population of white postmenopausal women with vitamin D insufficiency, found that 8.8% of patients developed hypercalcemia (>2.55 mmol/L), i.e. a prevalence not different from that seen in the small studies of sarcoidosis patients with vitamin D insufficiency following vitamin D/calcium supplementation (4 to 7.6%, Table 1). Therefore, sarcoidosis patients with vitamin D insufficiency do not seem to be at a higher risk of developing hypercalcemia than do other patients commonly administered vitamin D. We believe the benefits of calcium and vitamin D supplementation in sarcoidosis have not been sufficiently examined to determine whether the risk of hypercalcemia outweighs the benefits.

Conclusion

Vitamin D and calcium disturbances clearly play a principal role in the pathophysiology of sarcoidosis, yet the practical management remains controversial. Because of the concerns of worsening abnormal calcium metabolism following vitamin D supplementation, the clinical community has been ambivalent on supplementation in vitamin D-deficient or -insufficient patients with sarcoidosis. This concern also limited the conduct of prospective clinical trials to address a novel but neglected aspect of vitamin D action in this population. A study in two distinct ethnic groups of patients with sarcoidosis has opened the door towards further unraveling the role of vitamin D. The result of the study showing that repletion of 25-(OH)D may reverse some underlying pathophysiological abnormalities was compelling; the associated lowering of serum angiotensin-converting enzyme (ACE) and serum γ-globulin, both surrogate markers of active sarcoidosis, supports the suppression of granulomatous immune activity. These intervention studies were small in size and did not allow comprehensive investigation of the potential risk–benefit balance of vitamin D supplementation on different organ systems. Further prospective interventional investigation involving larger cohorts of patients is warranted to clarify the relationship between vitamin D repletion and inflammatory activity and outcome in sarcoidosis.

Acknowledgements

The authors thank Rubyth Aguirre and John Poindexter for their role in the preparation and submission of the manuscript and Xilong Li (Department of Population and Data Science) and Yulun Liu (Department of Population and Data Sciences) for their statistical support.

Contributions

Khashayar Sakaee and Connie Hsia prepared, wrote, and revised the manuscript. Fabiola Gianella compiled the data.

References

1. Bell NH, Stern PH, Pantzer E, et al.: Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest. 1979; 64(1): 218–25. PubMed Abstract | Publisher Full Text | Free Full Text

2. Papapoulos SE, Fraher LJ, Sandler LM, et al.: 1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet. 1979; 1(8117): 627–30. PubMed Abstract | Publisher Full Text

3. Albright F, Carroll EL, Dempsey EF, et al.: The cause of hypercalcuria in sarcoidosis and its treatment with cortisol and sodium phytate. J Clin Invest. 1956; 35(11): 1229–42. PubMed Abstract | Publisher Full Text | Free Full Text

4. Bell NH, Bartter FC: Transient reversal of hyperabsorption of calcium and of abnormal sensitivity to vitamin D in a patient with sarcoidosis during episode of nephritis. Ann Intern Med. 1964; 61: 702–10. PubMed Abstract | Publisher Full Text
5. Bell NH, Gill JR, Barter FC: On the abnormal calcium absorption in sarcoidosis. evidence for increased sensitivity to vitamin D. Am J Med. 1964; 36: 500–13.

6. Anderson J, Harper C, Dent CE, et al.: Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcinemia possibly antagonistic actions of cortisone and vitamin D. Lancet. 1954; 287(6481): 720–4.

7. Barbour GL, Coburn JW, Stalpolsky E, et al.: Hypercalcinemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med. 1981; 306(6): 440–3.

8. Adams JS, Sharma OP, Gacid MA, et al.: Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983; 72(5): 1856–60.

9. Mason RD, Frankle T, Chan YL, et al.: Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984; 100(1): 59–61.

10. Inui N, Murayama A, Sasaki S, et al.: Correlation between 25-hydroxyvitamin D3 1-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001; 110(9): 687–93.

11. Fuss M, Peperack J, Gillet C, et al.: Calcium and vitamin D metabolism in granulomatous diseases. Clin Rheumatol. 1992; 11(1): 39–36.

12. Capolongo G, Xu LHR, Accardo M, et al.: Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med. 2016; 64(5): 1025–34.

13. Prasse A, Katic C, Germann M, et al.: Phenotypic sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008; 177(3): 330–6.

14. Du Bois RM, Goh N, McGrath D, et al.: Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med. 2003; 253(1): 4–17.

15. Arkema EV, Grunewald J, Kullberg S, et al.: Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016; 48(1): 1690–9.

16. Baughman RP, Field S, Costabel U, et al.: Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016; 13(8): 1244–52.

17. Dumas O, Abramovitz L, Wise AS, et al.: Epidemiology of Sarcoidosis in a Prospective Cohort Study of U.S. Women. Ann Am Thorac Soc. 2016; 13(1): 67–71.

18. Byg KE, Milman N, Hansen S: Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vascul Dis Lung Lymphatics. 2003; 20(1): 46–52.

19. Hillerdal G, Nøe E, Ostrem K, et al.: Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984; 130(1): 29–32.

20. Morimoto T, Azuma A, Abe S, et al.: Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008; 31(2): 372–9.

21. Kulzer DA, Judson MA: New advances in the management of pulmonary sarcoidosis. BMJ. 2019; 367: i55533.

22. Brito-Zerón P, Sellarès J, Bosch X, et al.: Sarcoidosis: epidemiology and prognosis. Faculty Opinions Recommendation.

23. Deuelbiss U, Gomperli A, Schindler C, et al.: Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. 2010; 35(5): 1088–97.

24. Rybccki BA, Major M, Popovich J, et al.: Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997; 146(3): 234–41.

25. Kowalska M, Niewiadomska E, Ziejda JE: Epidemiology of sarcoidosis recorded in 2006–2010 in the Silesian voivodeship on the basis of routine medical reporting. Ann Agric Environ Med. 2014; 21(1): 55–58.

26. Judson MA, Boon AD, Lackland DT: The clinical course of sarcoidosis: Presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vascul Dis Lung Lymphatics. 2012; 29(3): 119–27.

27. Zadshir A, Tareen N, Pan D, et al.: The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Etno Dis. 2005; 18(4 Suppl 5): S8–97–101.

28. Gallagher JC, Sai AJ: Vitamin D insufficiency, deficiency, and bone health. J Clin Endocrinol Metab. 2010; 95(6): 2630–33.

29. Lemire JM: Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem. 1992; 49(1): 26–31.

30. Holick MF, Richtand NH, McNeil SC, et al.: Isolation and identification of previtamin D3 from the skin of rats exposed to ultraviolet irradiation. Biochemistry. 1979; 18(6): 1003–8.

31. Holick MF, Maclaughlin JA, Clark MB, et al.: Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980; 210(4466): 203–5.

32. Jones G, Prosser DE, Kaufmann M: 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012; 523(1): 9–18.

33. Chen TC, Chimeh F, Lu Z, et al.: Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys. 2007; 460(2): 213–7.

34. Cheng JB, Levine MA, Bell NH, et al.: DMC evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004; 101(20): 7711–5.

35. Holick MF, Maclaughlin JA, Doppelt SH: Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science. 1991; 211(4482): 590–3.

36. Fraser DR: Regulation of the metabolism of vitamin D. Physiol Rev 1980; 60(2): 551–613.

37. Kremer R, Goltzman D: Parathyroid hormone stimulates mammalian renal 25-hydroxyvitamin D3 1 alpha-hydroxylase in vitro. Endoocrinology. 1982; 110(1): 294–6.

38. Murayama A, Takeyama K, Kitanaka S, et al.: The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitriol, and 1 alpha,25(OH)2D3. Biochem Biophys Res Commun. 1998; 249(1): 11–6.

39. Shimada T, Kalaitis M, Yamazaki Y, et al.: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4): 561–8.

40. Evans RM: The steroid and thyroid hormone receptor superfamily. Science. 1988; 240(4854): 889–95.

41. Raisz LG, Kream BE: Regulation of bone formation. N Engl J Med. 1983; 309(1): 29–35.

42. Tanaka Y, DeLuca HF: Bone mineral mobilization activation of 1,25-dihydroxycholecalciferol, a metabolite of vitamin D. Arch Biochem Biophys. 1979; 146(2): 574–8.

43. Kongsbak M, von Essen MR, Leving TB, et al.: Vitamin D-binding protein controls T cell responses. J Immunol. 2014; 195: 25–35.

44. Morgan JW, Reddy GG, Uskokovic MR, et al.: Functional block for 1 alpha,25-dihydroxyvitamin D3-mediated gene regulation in human B lymphocytes. J Biol Chem. 1994; 269(18): 13437–43.
production in human B cells. Eur J Immunol. 2008; 38(8): 2210–8.

50. Correale J, Yousaati MC, Gaitan M: Immune-regulatory effects of vitamin D in multiple sclerosis. Brain. 2009; 132(Pt 5): 1146–66.

51. von Essen MR, Kongsbak M, Schjerling P, et al.: Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol. 2010; 11(4): 344–49.

52. Bakdash G, van Capel TAM, Mason LMK, et al.: Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells. Vaccine. 2014; 32(47): 5294–302.

53. Bhalla AK, Amento EP, Clemens TL, et al.: Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 1983; 57(6): 1308–10.

54. Provvedini DM, Takeas CD, Detmers J, et al.: 1,25-dihydroxyvitamin D3 receptors in human leucocytes. Science. 1983; 221(4616): 1181–3.

55. Brennan A, Katz DR, Numm JD, et al.: Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroyxycalciferol. Immunology. 1987; 61(4): 457–61.

56. Morgan JW, Kousseff N, Ford D, et al.: Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. Endocrinology. 2000; 141(9): 9225–34.

57. Dankers W, Colin EM, van Hamburg JP, et al.: Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front Immunol. 2016; 7: 697.

58. Correale J, Yousaati MC, Gaitan M: Immune-regulatory effects of vitamin D in multiple sclerosis. Brain. 2009; 132(Pt 5): 1146–66.

59. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 19(5): 6030–5.

60. Adams JS, Hewison M: Extrarenal expression of the 25-hydroxyvitamin D1-hydroxylase. Arch Biochem Biophys. 2012; 523(1): 95–102.

61. Trinchieri G, Shevach EM, et al.: Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2000; 3(1): 79–89.

62. Adams JS, Hewison M: Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4(2): 80–93.

63. Liu PT, Stenger S, Li H, et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768): 1770–3.

64. Wang TT, Nestel FP, Bourdoux V, et al.: Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004; 173(5): 2909–12.

65. Grumbach AF, Bonearda N, Koehler HP: Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005; 19(9): 1067–77.

66. Richmond BW, Drake WP: Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: Insights from mycobacterial research. Curr Opin Pulm Med. 2010; 16(6): 461–4.

67. Korcok E, Pur Ozyi̇lti̇ L, Ortaçȯy M, et al.: Cathelicidin as a link between sarcoidosis and tuberculosis. Sarcoidosis Vasc Diffuse Lung Dis. 2015; 32(3): 222–7.

68. Barroso BP, Culver DA, Chackwala A, et al.: Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Intern Med. 2012; 45(5–6): 569–78.

69. Sadeghi K, Wesner B, Lagrue N, et al.: Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006; 36(2): 361–70.

70. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature. 1990; 363(6403): 787–93.

71. Romagnani S: Regulation of the T cell response. Clin Exp Allergy. 2006; 36(11): 1357–68.

72. Lemire JM, Archer DC, Beck L, et al.: Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. J Nutr. 1995; 125(6 Suppl): 1704S–1708S.

73. Boonstra A, Barrat FJ, Cua DJ, et al.: In vitro generation of interleukin 10-producing regulatory T cells induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1-) and Th2-inducing cytokines. J Exp Med. 2002; 195(5): 603–16.

74. Conron M, Young C, Beynon HL: Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford). 2000; 39(7): 707–13.

75. Vanhems P, Amor H, Amor H, et al.: Calcitriol suppresses antirenal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009; 182(8): 4624–32.

76. Burke RR, Rybicki BA, Rao DS: Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(2): 113–20.

77. Berti A, Gerecitano S, et al.: Vitamin D Binding Protein and the Biological Activity of Vitamin D. Clin Endocrinol (Oxf). 2012; 76(3): 315–25.

78. Adams JS, Hewison M: Toll-like receptors in innate immunity. Nat Immunol. 2005; 7(1): 1–14.

79. Adams JS, Hewison M: Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4(2): 80–93.

80. Liu PT, Stenger S, Li H, et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768): 1770–3.

81. Wang TT, Nestel FP, Bourdoux V, et al.: Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004; 173(5): 2909–12.

82. Strominger JL, Ehrlich SD: Sarcoidosis: The nephrologist’s perspective. Am J Kidney Dis. 2010; 55(5): 943–50.

83. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

84. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

85. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

86. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

87. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

88. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

89. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.

90. Berkus RM, Kono S, et al.: Toll-like receptors in innate immunity. J Clin Endocrinol Metab. 2010; 95(5): 1766–78.
93. Lebacq E, Desmet V, Verhaegen H: Renal involvement in sarcoidosis. Postgrad Med J. 1970; 46(538): 526–9. PubMed Abstract | Publisher Full Text | Free Full Text

94. Rodman JS, Maher RJ: Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Unix Clin North Am. 2000; 27(2): 275-85. PubMed Abstract | Publisher Full Text

95. Rizzato G, Fraosi P, Montemurro L: Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995; 50(5): 555–9. PubMed Abstract | Publisher Full Text | Free Full Text

96. Rizzato G, Colombo P: Nephrolithiasis as a presenting feature of chronic sarcoidosis: A prospective study. Sarcoidosis Vasc Diffuse Lung Dis. 1996; 13(2): 167–72. PubMed Abstract

97. Gupta R, Beaudet L, Moore J, et al.: Treatment of sarcoid granulomatous interstitial nephritis with adalimumab. NDT plus. 2009; 2(2): 139–42. PubMed Abstract | Publisher Full Text | Free Full Text

98. Rajakariar R, Sharples EJ, Raftrey MJ, et al.: Sarcoid tubulo-interstitial nephritis: Long-term outcome and response to corticosteroid therapy. Kidney Int. 2006; 70(1): 165–9. PubMed Abstract | Publisher Full Text

99. Robson MG, Banerjee D, Hopster D, et al.: Seven cases of granulomatous interstitial nephritis in the absence of extrarenal sarcoid. Nephrol Dial Transplant 2003; 18(2): 280–4. PubMed Abstract | Publisher Full Text | Free Full Text

100. Joss N, Morris S, Young B, et al.: Granulomatous interstitial nephritis. Clin J Am Soc Nephrol. 2007; 2(2): 222–30. PubMed Abstract | Publisher Full Text | Free Full Text

101. Eon Crouser ED, Maier LA, Wilson KC, et al.: Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201(8): e26–e51. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

102. Meyrier A, Valeyre D, Bouillon R, et al.: Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 and parameters of disease activity. O J Med. 1985; 54(151): 269–81. PubMed Abstract | Publisher Full Text

103. Zerwekh JE, Pak CY, Kaplan RA, et al.: Pathogenetic role of 1 alpha,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab. 1980; 51(2): 381–6. PubMed Abstract | Publisher Full Text

104. Haussler MR, Boyce DW, Littledike ET, et al.: A rapidly acting metabolite of vitamin D3. Proc Natl Acad Sci U S A. 1971; 68(1): 177–81. PubMed Abstract | Publisher Full Text | Free Full Text

105. Holick MF, Schnees HK, DeLuca HF, et al.: Isolation and identification of 1,25-dihydroxycholecalciferol: A metabolite of vitamin D active in intestine. Biochemistry. 1971; 10(14): 2799–804. PubMed Abstract | Publisher Full Text

106. Pak CY, Data M, Lawrence EC, et al.: The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J Clin Invest. 1974; 54(2): 387–400. PubMed Abstract | Publisher Full Text | Free Full Text

107. Broads AE, Insgona KL, Lang R, et al.: A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J Clin Endocrinol Metab. 1984; 58(1): 161–9. PubMed Abstract | Publisher Full Text | Free Full Text

108. Maierhofer WJ, Gray RW, Cheung HS, et al.: Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int. 1983; 24(4): 555–60. PubMed Abstract | Publisher Full Text | Free Full Text

109. Alon US: Nephrocalcinosis. Curr Opin Pediatr. 1997; 9: 160–5. Publisher Full Text

110. Sharma OP: Vitamin D, calcium, and sarcoidosis. Chest. 1996; 109(2): 535–9. PubMed Abstract | Publisher Full Text | Free Full Text

111. Adams JS, Diz MM, Sharma OP: Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalciemia with short-course chloroquine therapy. Ann Intern Med. 1989; 111(3): 437–8. PubMed Abstract | Publisher Full Text | Free Full Text

112. Barré PE, Gascon-Barré M, Meakins JL, et al.: Hydroxychloroquine treatment of hypercalciemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med. 1987; 82(6): 1259–62. PubMed Abstract | Publisher Full Text

113. O’Leary TJ, Jones G, Yip A, et al.: The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med. 1986; 315(12): 727–30. PubMed Abstract | Publisher Full Text

114. Adams JS, Sharma OP, Diz MM, et al.: Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalciemia. J Clin Endocrinol Metab. 1990; 70(4): 1095–10. PubMed Abstract | Publisher Full Text

115. Ejaz AA, Zabaneh RI, Tiwari P, et al.: Ketoconazole in the treatment of recurrent nephrolithiasis associated with sarcoidosis. Nephrol Dial Transplant. 1994; 9(10): 1492–4. PubMed Abstract | Publisher Full Text

116. Kruhlhoff KL, Gyekyo MR, Scheiman JM: Giant splenomegaly and refractory hypercalciemia due to extrapulmonary sarcoidosis. Successful treatment by splenectomy. Arch Intern Med. 1993; 153(24): 2793–6. PubMed Abstract | Publisher Full Text

117. Sharma OP, Alfaro C: Hypercalciuria and renal stones in a sarcoidosis patient treated by extracorporeal shockwave lithotripsy. Sarcoidosis. 1986; 3(1): 7–9. PubMed Abstract

118. Buckley L, Guyatt G, Fink HA, et al.: 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, Arthritis Rheumatol. 2017; 69(8): 1521–37. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

119. Gallagher JC, Smith LM, Yalamanchi V: Incidence of hypercalciuria and hypercalciuria during vitamin D and calcium supplementation in older women. Menopause. 2014; 21(11): 1173–80. PubMed Abstract | Publisher Full Text | Free Full Text